Indications
Xigduo is indicated in adults for the treatment of type 2 diabetes mellitus as an adjunct to diet and exercise:
- in patients insufficiently controlled on their maximally tolerated dose of metformin alone
- in combination with other medicinal products for the treatment of diabetes in patients insufficiently controlled with metformin and these medicinal products
- in patients already being treated with the combination of dapagliflozin and metformin as separate tablets. For study results with respect to combination of therapies, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.
Composition
- Active substance
- metformin hydrochloride, dapagliflozin propanediol monohydrate
- International name (INN)
- dapagliflozin;metformin
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.